Industry News


Cepheid Gets FDA Approval for Xpert CT/NG

Cepheid, Sunnyvale, Calif, has received FDA clearance for its Xpert® CT/NG.

Running on Cepheid’s GeneXpert® Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the first time, same-day patient consultation and treatment is possible for the two most common sexually transmitted bacterial infections in the United States, says the company.

johnbishopJohn Bishop“We are bringing to market a true next-generation molecular diagnostic product for detection of CT/NG—a test we designed from the ground up to provide accuracy, ease of use, and results availability,” says John Bishop, Cepheid’s CEO. “We expect this innovative diagnostic test to deliver new levels of confidence to clinicians, in addition to enabling same-day decisions about treating their patients the critical first step in effectively managing these epidemics.”

Based on the company’s experience with the biothreat detection program, where more than 11 million tests have been performed, it has learned that the best way to minimize gonorrhea false-positive results is to include more than one genetic target.

The tes thas several novel design features, according to David Persing, MD, PhD, Cepheid’s chief medical and technology officer. “First, our research team used in silico approaches to uncover multiple genomic targets for improving the accuracy of both CT and NG detection,” he says. “Second, we included a first-in-class sample adequacy control that we believe overcomes limitations of first-generation technologies and adds significantly to the interpretation of diagnostic results generated by the GeneXpert System.”

Gonorrhea and chlamydia are easily treated when detected and managed quickly. Chlamydia remains the most common sexually transmitted bacterial infection in the United States. While the Centers for Disease Control and Prevention (CDC) recommends annual testing for all sexually active women aged 25 and under, their most recent nationally representative estimate among this population found that only 38%  of sexually active women were tested for chlamydia during the previous year.1, 2

Gonorrhea is the second most commonly reported bacterial infectious disease in the country. The CDC estimates that more than 700,000 Americans become infected with gonorrhea every year, yet fewer than half of these infections are diagnosed and reported to the CDC. Current testing protocols for Neisseria gonorrhoeae are often problematic due to cross-reactivity with other organisms, often requiring an additional confirmatory test. These delays and coordination issues can significantly hamper communication and consultation, leaving both patients and their partners uninformed and untreated.3

[Source: Cepheid]

References

  1. http://www.cdc.gov/std/treatment/2010/chlamydial-infections.htm
  2. http://www.cdc.gov/nchhstp/newsroom/stdconference2012pressrelease.html
  3. http://www.cdc.gov/std/gonorrhea/STDFact-gonorrhea.htm